Physician profile
Trevor Lim
NPI 1669546164
$1,234.87
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $98.87 · 2021: $595 · 2022: $307 · 2023: $51.29 · 2024: $14.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $239.89 | 2020-2022 | |
| Janssen Biotech, INC. | $159.35 | 2019-2022 | |
| Varian Medical Systems, INC. | $99.99 | 2019 | |
| Eisai INC. | $83.91 | 2021-2022 | |
| Boston Scientific Corporation | $65.34 | 2021 | |
| Amgen INC. | $60.84 | 2021 | |
| Novocure INC. | $51.29 | 2023 | Optune |
| Genzyme Corporation | $47.33 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $39.65 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.77 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $34.64 | 2021 | |
| Merck Sharp & Dohme LLC | $33.30 | 2021 | |
| Dendreon Pharmaceuticals LLC | $32.91 | 2021 | |
| Morphosys, US INC. | $30.38 | 2022 | |
| Coherus Oncology, INC. | $25.37 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $23.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.62 | 2020 | |
| Dova Pharmaceuticals | $21.18 | 2019 | |
| Myovant Sciences INC. | $16.12 | 2022 | |
| Blueprint Medicines Corporation | $16.10 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $16.09 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.15 | 2021 | |
| Abbvie INC. | $14.01 | 2024 | |
| Incyte Corporation | $13.63 | 2020 | |
| Seagen INC. | $12.54 | 2022 | |
| Lilly USA, LLC | $12.35 | 2021 | |
| Taiho Oncology, INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.